Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania.
Mol Cancer Res. 2021 Apr;19(4):598-611. doi: 10.1158/1541-7786.MCR-20-0189. Epub 2021 Jan 11.
The role of PPAR gamma (PPARγ) has been well characterized in the developmental process of adipogenesis, yet its aberrant expression patterns and functions in cancer subtypes are less understood. Although PPARγ has been recently demonstrated to play non-cell-autonomous roles in promoting bladder urothelial carcinoma (UC) progression, underlying mechanisms of the cell-intrinsic oncogenic activity remain unknown. Here, we report robust expression and nuclear accumulation of PPARγ in 47% of samples of patients with UC, exceeding mRNA expression patterns published by The Cancer Genome Atlas. assays revealed for the first time that treatment of UC cells with PPARγ inverse agonist or knockout by CRISPR-Cas9 reduces proliferation, migration, and invasion of multiple established UC cell lines, most strongly in those characterized by genomic amplification or activating mutations of , the obligate heterodimer of PPARγ. Through genome-wide approaches including chromatin immunoprecipitation sequencing and RNA sequencing, we define a novel set of PPARγ-regulated genes in UC, including Sonic Hedgehog (). Similar to PPARγ, genetic inhibition of reduces proliferation and motility. Finally, we demonstrate the PPARγ dependency of UC tumors by genetic and pharmacologic PPARγ inhibition in subcutaneous xenografts. Collectively, our data indicate that PPARγ promotes UC progression in a subset of patients, at least in part, through cell-autonomous mechanisms linked to signaling. IMPLICATIONS: Genome-wide analysis of DNA-binding sites for oncogenic factor PPARγ revealed as a novel downstream target involved in UC progression, providing important insight into the tumorigenic nature and molecular mechanism of PPARγ signaling in UC.
过氧化物酶体增殖物激活受体γ(PPARγ)在脂肪生成的发育过程中的作用已得到很好的描述,但在癌症亚型中其异常表达模式和功能了解较少。尽管最近已经证明 PPARγ 在促进膀胱癌(UC)进展中发挥非细胞自主作用,但细胞内致癌活性的潜在机制尚不清楚。在这里,我们报告在 47%的 UC 患者样本中发现 PPARγ 表达丰富且核积累,超过了癌症基因组图谱发表的 mRNA 表达模式。功能测定首次表明,用 PPARγ 反向激动剂或 CRISPR-Cas9 敲除处理 UC 细胞可降低多种已建立的 UC 细胞系的增殖、迁移和侵袭,在那些具有 基因组扩增或激活突变的细胞中作用最强,是 PPARγ 的必需异二聚体。通过包括染色质免疫沉淀测序和 RNA 测序在内的全基因组方法,我们定义了 UC 中一组新的 PPARγ 调节基因,包括 Sonic Hedgehog ()。与 PPARγ 相似,遗传抑制 可减少增殖和运动性。最后,我们通过皮下异种移植中的遗传和药理学 PPARγ 抑制证明了 UC 肿瘤的 PPARγ 依赖性。总的来说,我们的数据表明,在一部分患者中,PPARγ 通过与 信号相关的细胞自主机制促进 UC 进展。
这是一篇关于过氧化物酶体增殖物激活受体γ(PPARγ)在膀胱癌(UC)中的作用及其分子机制的研究论文。研究发现,PPARγ 在一部分 UC 患者中表达丰富且核积累,通过与 Sonic Hedgehog () 信号相关的细胞自主机制促进 UC 进展。这为 UC 的肿瘤发生机制和治疗提供了新的思路和靶点。